Find Your Broker
Share Name Share Symbol Market Type Share ISIN Share Description
Angle Plc LSE:AGL London Ordinary Share GB0034330679 ORD 10P
  Price Change % Change Share Price Shares Traded Last Trade
  +0.00p +0.00% 53.00p 21,641 08:00:00
Bid Price Offer Price High Price Low Price Open Price
52.00p 54.00p 53.00p 53.00p 53.00p
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Support Services 0.63 -8.93 -10.09 76.0

Angle (AGL) Latest News

More Angle News
Angle Takeover Rumours

Angle (AGL) Share Charts

1 Year Angle Chart

1 Year Angle Chart

1 Month Angle Chart

1 Month Angle Chart

Intraday Angle Chart

Intraday Angle Chart

Angle (AGL) Discussions and Chat

Angle (AGL) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
10:13:1452.5510,0005,255.00O
09:51:3253.753,5001,881.25O
09:50:4353.565,0002,678.00O
09:49:1653.5618699.62O
08:58:2352.502,9551,551.38O
View all Angle trades in real-time

Angle (AGL) Top Chat Posts

DateSubject
21/1/2019
08:20
Angle Daily Update: Angle Plc is listed in the Support Services sector of the London Stock Exchange with ticker AGL. The last closing price for Angle was 53p.
Angle Plc has a 4 week average price of 38.50p and a 12 week average price of 38p.
The 1 year high share price is 76.50p while the 1 year low share price is currently 38p.
There are currently 143,486,522 shares in issue and the average daily traded volume is 328,331 shares. The market capitalisation of Angle Plc is £76,047,856.66.
10/1/2019
16:35
sicilian_kan: Massively overbought for a device used in a mouse study. What's the benefit to AGL so far? A few single digit £1,000s in potential sales revenues of cartridges for a P1 clinical trial? Yet the share price goes up by over £40m? - for the device? The market has just valued the actual drug at about £1bn. At the mouse study stage!? Bonkers. Expecting a big fall tomorrow.
21/12/2018
07:37
4legs: Incentives are all very well when earned. I don't feel they should be set up when the share price has fallen to a low. I know we have had lots of good news, though this has only had a temporary positive effect on the share price, which would seem to indicate something has been missing in the strategy. Hence I don't see why incentives are due at this stage. Hopefully we are nearing more permanent growth.
10/12/2018
23:15
escapetohome: My warning of the “ false gimmick trend “ back in Jan 2016. Now nearly 3 years later the share price is far below where were then. No progress. 3 years of the same pilfering gabbering gibberish of pounds not pence. Yet we clearly still a pence company. I will repeat again, I would be over the moon with 70 p , this is a dithering company which failed to take the right step, which was to take on board a partner with deep pockets early on. escapetohome - 28 Jan 2016 - 09:06:10 - 608 of 10519 ANGLE 2016 – LIQUID BIOPSY TAKEOVER TARGET - AGL Once again be aware the market maker " false gimmick trend" . This time they will be operating the other direction manipulating the share down to confuse allinto selling. The reality is there is a step forward, and the share price deserves higher. 1
06/12/2018
10:46
alloa2003: Brexit is not helping sentiment but not the reason for AGL share price weakness. There is literally no interest in the stock at the moment - going to be news driven for some time to come until we see sales and profits. Might drift until it finds support.
06/12/2018
10:34
toffeeman: Brexit has absolutely jack sh1t to do with AGL's share price.
23/8/2018
17:49
andypar: I'm a huge fan of AGL. Simple, high margin, high barriers to entry. Here are a few of my thoughts. Dilution hell or screening heaven ? Are the collaborations already in place all set up for FDA approval,so the moment we get it then the revenue can start kicking in ? I don't want to be reading a year after FDA that they are trying to establish sales channels etc. If the revenue does not ramp up very quickly then there will be more shares issued and we will be back to the famous AIM story of Jam Tomorrow. The big $$$ takeover that we all hope for will only occur from a position of strength ie sales and a strong balance sheet. Otherwise we will be diluted into oblivion and maybe saved at the last by a takeover on the cheap. With our current cost base we need approx. $15m in revenue to breakeven. We need at least $5m in sales the year following FDA and it to double year on year thereafter. I want everything ready to go and all the trumpets blaring when we get FDA. If the share price doubles or triples post FDA approval do another capital raise then for say $25m (hopefully the last). Don't forget we will need to fund further trials to get approval from the FDA for other cancers. This should be considerably less arduous than it has been for the MBC. Also post FDA approval I want AGL start talking about blood test screening. That would put the share price into orbit (also less dilution etc). Big pharma and the city could not fail to see the potential $$$$$$. A trial of 100 apparently fit people over 65 to see if they could pick up CTC's in any of the subjects. If the trial gave positive results ie picked up CTC's in say 5 of the subjects and led to potentially earlier diagnnosis and treatment. It would add a lot of $$$$$ to the market cap, even if real life screening was still 10 years away. It is much easier to talk about a market cap of billions when AGL talks screening :o) Everyone understands screening and the potential $$$$$$$$$$$$$$. AGL would be mad once we have to FDA approval not to exploit this. Get the market cap up, get us off AIM. Put us in the shop window as the future of medicine.
22/8/2018
16:47
mikepompeyfan: In the absence of significant buying market makers lower a share price to drum up buying interest. They make their money on the spread so do all they can to generate turnover. They don't care at what share price. As a news driven share the price will soon be up again when it comes.
09/7/2018
10:25
jelenko: The question is how much would we charge for a license? I think good trial results and the share price would start to factor in FDA approval. Remember how quickly it raced to 79p on the Bart's prostate news last year. This time the magnitude of the rise would be greater, I think we all know that. I have a simple way of looking at the share price potential especially when we have a meaningful revenue number( at some future date) Every £10m in revenue @75% margin and 15 PE would equate to 79p share price. Every £100m in revenue £790p. The market is enormous and you would think that with FDA £100m should be easily attainable. Especially when the market size the company talks about is valued in £bilions.
26/3/2018
08:17
alloa2003: I think AGL share price suffers from boredom at times between announcements. Very news driven as profitability is some way off.
24/12/2017
11:06
alloa2003: Its that time of year - what are your predicitons for the AGL share price in 12 months? I will start at £2 a share :)
Angle share price data is direct from the London Stock Exchange
Your Recent History
LSE
AGL
Angle
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190121 10:37:21